Medication-induced hyperglycemia: pediatric perspective
| العنوان: | Medication-induced hyperglycemia: pediatric perspective |
|---|---|
| المؤلفون: | Maria J. Redondo, Mustafa Tosur, Marcela Astudillo, Johanna M. Viau-Colindres, Sarah K. Lyons |
| المصدر: | BMJ Open Diabetes Research & Care, Vol 8, Iss 1 (2020) BMJ Open Diabetes Research & Care |
| بيانات النشر: | BMJ, 2020. |
| سنة النشر: | 2020 |
| مصطلحات موضوعية: | Drug, medicine.medical_specialty, Prescription Drugs, pediatrics, Drug-Related Side Effects and Adverse Reactions, endocrine system diseases, Endocrinology, Diabetes and Metabolism, media_common.quotation_subject, 030209 endocrinology & metabolism, Clinical Care/Education/Nutrition, Amiodarone, Diseases of the endocrine glands. Clinical endocrinology, 03 medical and health sciences, medications, 0302 clinical medicine, Diabetes mellitus, Humans, Medicine, 030212 general & internal medicine, Family history, Child, Intensive care medicine, media_common, business.industry, pancreatic diabetes, nutritional and metabolic diseases, RC648-665, medicine.disease, Obesity, Tacrolimus, Clonidine, Hyperglycemia, business, medicine.drug, Hormone |
| الوصف: | Medication-induced hyperglycemia is a frequently encountered clinical problem in children. The intent of this review of medications that cause hyperglycemia and their mechanisms of action is to help guide clinicians in prevention, screening and management of pediatric drug-induced hyperglycemia. We conducted a thorough literature review in PubMed and Cochrane libraries from inception to July 2019. Although many pharmacotherapies that have been associated with hyperglycemia in adults are also used in children, pediatric-specific data on medication-induced hyperglycemia are scarce. The mechanisms of hyperglycemia may involve β cell destruction, decreased insulin secretion and/or sensitivity, and excessive glucose influx. While some medications (eg, glucocorticoids, L-asparaginase, tacrolimus) are markedly associated with high risk of hyperglycemia, the association is less clear in others (eg, clonidine, hormonal contraceptives, amiodarone). In addition to the drug and its dose, patient characteristics, such as obesity or family history of diabetes, affect a child’s risk of developing hyperglycemia. Identification of pediatric patients with increased risk of developing hyperglycemia, creating strategies for risk reduction, and treating hyperglycemia in a timely manner may improve patient outcomes. |
| تدمد: | 2052-4897 |
| URL الوصول: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fbe43b6053021b60a940ab5759bd12d4 https://doi.org/10.1136/bmjdrc-2019-000801 |
| حقوق: | OPEN |
| رقم الأكسشن: | edsair.doi.dedup.....fbe43b6053021b60a940ab5759bd12d4 |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 20524897 |
|---|